Skip to main content

Progyny Inc

For the period ended Dec 31, 2023. Filed Feb 29, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 29, 2024

PGNY$35.95+3.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

SIGNATURES

Pursuant to the requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PROGYNY, INC.
Date: February 29, 2024By:/s/ PETER ANEVSKI
Peter Anevski
Chief Executive Officer
(Principal Executive Officer)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Peter Anevski and Mark Livingston, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated as of February 29, 2024.

SignatureTitle
/s/ PETER ANEVSKIChief Executive Officer and Director
Peter Anevski(principal executive officer)
/s/ MARK LIVINGSTONChief Financial Officer
Mark Livingston(principal financial and accounting officer)
/s/ DAVID SCHLANGERExecutive Chairman
David Schlanger/s/ BETH SEIDENBERGLead Independent Director
Beth Seidenberg, M.D.
/s/ LLOYD DEANDirector
Lloyd Dean
/s/ FRED COHENDirector
Fred Cohen, M.D., D.Phil.
/s/ KEVIN GORDONDirector
Kevin Gordon
/s/ ROGER HOLSTEINDirector
Roger Holstein
/s/ JEFFREY PARKDirector
Jeffrey Park
/s/ NORMAN PAYSONDirector
Norman Payson, M.D.
/s/ CHERYL SCOTTDirector
Cheryl Scott
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.